The rationale for the development of hesperidin as a safer and more potent anticancer agent for NSCLC is based on its ability to inhibit the migratory and invasive capabilities of A549 human NSCLC cells through modulation of the stromal-cell derived factor-1 (SDF-1)/C-X-C motif chemokine receptor 4 (CXCR-4) signaling cascade [297]. The gene discussed is CXCR4; the disease is non-small cell lung carcinoma.